NPS Pharmaceuticals (NPSP) Misses Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Canaccord Keeps NPS Pharma (NPSP) at 'Buy'; Some Centers Slower to Put Patients on Gattex
November 11, 2014 11:07 AM ESTCanaccord Genuity affirms NPS Pharmaceuticals (Nasdaq: NPSP) at Buy with a price target of $42 following Q3 results reported Monday night.
Analyst John Newman noted that Gattex growth of about 18.6 percent over Q2 was flat with expectations, but guidance of $100 to... More
